EGFR and inflammatory breast carcinoma: Although our results highlight the clinical significance of targeting both the EGFR and COX-2 pathways in patients with IBC, we recognize that combination treatment of EGFR and COX-2 inhibitors in breast cancer has not been clinically successful.